BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State

Bothell-Based Provider of Biopreservation Tools for Cells, Tissues, and Organs

Jul 02, 2015, 06:00 ET from BioLife Solutions, Inc.

BOTHELL, Wash., July 2, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that Seattle Business Magazine has included BioLife in its annual list of the 100 best companies to work for in Washington state for 2015.

Now in its 24th year, this competition salutes Washington companies setting the standard for leadership, strong benefits, ideal work environment, innovative training, happiest employees and more.  Winners were recognized at an awards dinner held on July 1st at the Washington State Convention Center.

Mike Rice, BioLife's Chief Executive Officer, commented, "Our entire team is very honored and proud to receive this recognition for the second time in three years.  We have a very special corporate culture, based on merit, authentic communication, and teamwork. I'm honored to lead our highly capable and dedicated team at BioLife.  Our team members are acutely aware of the role BioLife plays as a critical life science tools supplier to the leading regenerative medicine, biobanking, and drug discovery companies and institutions throughout the world."

For the complete list of winning companies, please visit: http://seattlebusinessmag.com.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol® and CryoStor® biopreservation media products are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's proprietary products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  This enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, projected financial results, new products, and third party projections regarding the future market for regenerative medicine and cold chain packaging and instrumentation services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; reliance upon SAVSU for completing the development and manufacturing of biologistex CCM's products; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations

Daphne Taylor

Senior Vice President, Chief Financial Officer

(425) 402-1400

dtaylor@biolifesolutions.com

 

SOURCE BioLife Solutions, Inc.



RELATED LINKS

http://www.biolifesolutions.com